Return to search

Xilio Therapeutics snags $100.5m Series B

Waltham, Massachusetts-based Xilio Therapeutics, a developer of immuno-oncology therapies for patients with cancer, has secured $100.5 million in Series B financing.

Waltham, Massachusetts-based Xilio Therapeutics, a developer of immuno-oncology therapies for patients with cancer, has secured $100.5 million in Series B financing. Takeda Ventures Inc led the round.

Source: Press Release